ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 436

Synthetic Anti-CCP Antibody Aggravated Severity of Animal Arthritis and Captured Citrullinated Antigen in the Serum of Patients with Rheumatoid Arthritis

Youngkyun Kim1, Su-Jin Moon2, Hyoju Yi2 and Ji Hyeon Ju3, 11Convergent Research Consortium for Immunologic Disease, The Catholic University of Korea, Seoul, South Korea, 2Rheumatology, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 3Rheumatology, College of Medicine, The Catholic University of Korea & Stanford University, Seoul & Palo Alto, CA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-CCP antibodies, citrulline and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenisis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Auto-antibodies against citrullinated protein antigens (ACPA) have shown their relevance for the prognosis and diagnosis of rheumatoid arthritis (RA), and have been implicated in disease pathogenesis. However, the exact pathologic relevance of these antibodies remains unclear. To obtain insight into this question, we tried to synthesize ACPA and then apply it to animal model and human samples.  

Methods: Using hybridoma technology, an IgG monoclonal antibody (mAb), 12G1 was developed against a cyclic-citrullinated peptide (CCP). Clones were selected on the basis of not reacting with control peptide (CRP) which was included one arginine instead of citrulline on the same peptide sequence and structure, but reacting well with synthetic CCP. After successful establishment of hybridoma for anti-CCP Ab, we analyzed the characteristics of this synthetic anti-CCP Ab. 12G1 was challenged to collagen induced arthritis (CIA) model. Western blot with 12G1 was done on the serum samples of RA patients (n=25) and non-RA control (n=23).  Synovium of CIA and RA patients were immunostained with 12G1.

Results: Immunohistochmical analysis with 12G1 revealed positive staining result in CIA and RA patients in comparison with control samples of wild type mice and osteoarthritis. Western blot analysis of sera from RA patients had stronger 12G1-positive bands of citrullinated protein compared with non-RA controls. Average band density was four times higher in RA than non-RA (p=0.001). These western results showed the meaningful correlation with 2nd generation commercial Anti-CCP Ab diagnostic kit (n=48, p=0.02). Moreover, to evaluate the direct role of generated anti-CCP Ab, mice were immunized with CII and then injected with 12G1 instead of second boosting. Immunized mice with 12G1 demonstrated significantly increased disease severity and incidence compared with mice challenged with negative control.

Conclusion: In conclusion, we generated a synthetic monoclonal antibody against CCP. This antibody exacerbated arthritis in CIA model and had the potential to detect citrullinated Ag in human RA serum. Application of this anti-CCP Ab may contribute to understanding the pathophysiology of RA and developing synthetic Ab-driven diagnostic strategy.


Disclosure:

Y. Kim,
None;

S. J. Moon,
None;

H. Yi,
None;

J. H. Ju,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/synthetic-anti-ccp-antibody-aggravated-severity-of-animal-arthritis-and-captured-citrullinated-antigen-in-the-serum-of-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology